ADMA Biologics Inc vs Star Bulk Carriers Corp — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Star Bulk Carriers Corp trades at $27.66 (market cap $3.09B). The key difference: Star Bulk Carriers Corp is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SBLK | |
|---|---|---|
Market Cap | $2.22B | $3.09B |
Sector | Health | Industrials |
52-Week High | $20.38 | $29.15 |
52-Week Low | $7.60 | $16.79 |
Enterprise Value | $2.29B | $3.77B |
Dividend Yield | — | 6.79% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Star Bulk Carriers (SBLK) trades at $28.90, up 1.08% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $1.21 per share, and declared a $0.90 dividend. Fundamentals show robust profitability with a net income margin of 23.87% and a P/E ratio of 11.15, indicating potential value. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though the impact appears neutral.
The outlook for SBLK is positive, driven by strong earnings growth, healthy cash flow, and a favorable analyst consensus with 58.34% buy ratings. Key opportunities include high dividend yields and operational efficiency, while risks involve dry bulk rate volatility and competitive pressures in the shipping sector. Investors should weigh the company's solid financials against industry cyclicality.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →